Andrea Garcia, JD, discusses newest research on Omicron | COVID-19 Update for Jan. 26, 2022

AMA CXO Todd Unger reviews COVID-19 vaccine numbers and trending topics related to the pandemic over the past week with AMA Director of Science, Medicine and Public Health Andrea Garcia, JD, MPH. Also covering the World Health Organization's (WHO) opinion on life post-Omicron, as well as newly published data from the CDC, JAMA, and what that research means in the battle against the current U.S. COVID surge. Additionally, the FDA has revised authorizations for two monoclonal antibody treatments—a topic AMA's immediate past-president, Susan Bailey, MD, will be discussing in an upcoming webinar with experts from the FDA.

The webinar: "COVID-19: What to know about therapeutics and other treatment options" is scheduled for Tuesday, Feb. 1, at 3 p.m. Central time.

0:00 AMA COVID-19 Update for January 26, 2022
0:34 What does the COVID case-count look like currently?
1:30 Are we on the other side of this Omicron surge?
2:47 Is this following the same pattern seen in South Africa where Omicron was first identified?
3:26 What do we think post-Omicron will look like in the U.S.?
4:34 What did health officials at the WHO have to say this week?
5:42 What do we know about immunity from an Omicron infection?
6:39 Does that mean people who are vaccinated and have had a breakthrough infection can feel comfortable living a fairly normal life—at least in the months following recovery?
7:39 What does the recent data published by the CDC tell us about vaccine effectiveness and Omicron?
8:48 Did anything new emerge from these reports?
9:27 What exactly did the researchers examine for these studies?
10:31 How many people are vaccinated against COVID-19 in the U.S.?
11:14 Why did the FDA revise authorizations for two monoclonal antibody treatments?
12:14 What did the AMA say in support of this decision?